IPO
The company focuses on developing a novel class of drugs called Bicycles. Bicycles are fully synthetic short peptides constrained to form two loops—hence “bi” cycles—that stabilize their structural geometry.
Pharming Group N.V. announces that at its Annual General Meeting of shareholders, all proposals were approved.
Motif Bio plc, a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, announces that at the Company’s AGM held earlier the Company provided the following review of key aspects of its business and growth strategy.
Biotech company Athera announce the closing of new share issue, raising in total 55 million SEK from current major shareholders including Industrifonden and Östersjöstiftelsen, together with new shareholders from the Sciety network of investors.
Promore Pharma’s most important task is to develop new products aiming to improve the quality of life for patients with difficult-to-treat wounds and various types of scarring, primarily following surgery.
Auris Medical Holding Ltd. announced that it has received written notification from the Nasdaq Hearings Panel notifying the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550 for continued listing on The Nasdaq Capital Market.
Auris Medical Holding Ltd. announced today the closing of its previously announced underwritten public offering
GeoVax Labs, Inc. announced its financial results for the three months ended March 31, 2019 and provided an update on its corporate development progress.
Evotec SE reported financial results and corporate updates for the first quarter of 2019.
Soligenix, Inc. announced its recent accomplishments and financial results for the quarter ended March 31, 2019.
PRESS RELEASES